Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Seminars in Oncology|December 3, 2014
GD2-targeted immunotherapy and radioimmunotherapyKonstantin Dobrenkov, Nai-Kong V CheungPediatric Emergency Care|May 8, 2012
Paroxysmal neuropathic pain in an adolescent female with syringomyelia: a review of literatureMuhammad Waseem, Andaleeb Raja, Erin Jeun, et al.Anticancer Research|April 9, 2005
Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cellsHideki Kimura, Konstantin Dobrenkov, Tomohiko Iida, et al.Pediatric Blood & Cancer|June 16, 2016
Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adultsKonstantin Dobrenkov, Irina Ostrovnaya, Jessie Gu, et al.European Journal of Nuclear Medicine and Molecular Imaging|March 5, 2009
PET imaging of HSV1-tk mutants with acquired specificity toward pyrimidine- and acycloguanosine-based radiotracersYury Likar, Konstantin Dobrenkov, Malgorzata Olszewska, et al.Oncoimmunology|July 7, 2017
Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2Sayed Shahabuddin Hoseini, Konstantin Dobrenkov, Dmitry Pankov, et al.Cancer|August 19, 2020
First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumorsRavit Geva, Mark Voskoboynik, Konstantin Dobrenkov, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 17, 2008
A new acycloguanosine-specific supermutant of herpes simplex virus type 1 thymidine kinase suitable for PET imaging and suicide gene therapy for potential use in patients treated with pyrimidine-based cytotoxic drugsYury Likar, Konstantin Dobrenkov, Malgorzata Olszewska, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid TumorsKyriakos P Papadopoulos, Karen Autio, Talia Golan, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 17, 2008
Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imagingKonstantin Dobrenkov, Malgorzata Olszewska, Yury Likar, et al.Pageof 2